4-6 Weeks for Initial Results
Raptamer Discovery Group uses our innovative, non-SELEX process, which has been developed and refined over the past two decades by leaders in the aptamer field. We conduct a fast, single-round selection against your targets using our proprietary library.
Raptamer Discovery Group uses next-generation sequencing technology to identify the nucleotide sequencing in each Raptamer™ candidate, and we use this information and our library data to identify the complete chemical structure, including side chains.
Using our sophisticated bioinformatics platform, we rank Raptamer™ candidates by their predicted performance. We have a good sense of candidate quality at this point, and will give you feedback on how the process is going.
We synthesize the highest-ranked Raptamer™ candidates for each target at a 50 nmol scale for use in our internal binding studies.
We test each of the Raptamer™ candidates for binding against your target using the sophisticated ForteBio Octet Red biomolecular interaction platform. We share these results with you to decide which candidates you want made at a medium scale.
We synthesize up to 4 candidates at 2 ?mol scale, and prepare vials for shipping to you for use in the next steps of your development process.
Traditional aptamers use just four nucleotides: A, C, G, and T (in the case of DNA aptamers) and A, C, G, and U (in the case of RNA aptamers).
Raptamers™ go further. We generate next-generation aptamers with a backbone made up of standard DNA nucleotides, plus a number of amino acid side chains, through a series of custom modifications that are part of our proprietary process. The side chains give our Raptamers™ more diversity, stronger binding, and increase hydrophobicity, increasing both specificity and antibody-like behavior.
Finally, we have developed a large number of custom modifications that can push binding affinity even further, into the picomolar range.
KD determination for the binding of O.2.1 aptamer to mouse OPG in buffer by biolayer interferometry (Octet RED96, Forte Bio). Global fitting was performed assuming a 1:1 binding model. KD ~1 pM. R2 0.99817.
KD determination of PLDH binding to aptamers PLDH-M-86 and PLDH-M-106 using the ELONA assay as defined by nonlinear least square curve fitting in buffer conditions. Resulting KDs are 32 nM and 12 nM respectively.
Thrombin aptamer shows enhanced binding affinity when modified with indole or phenol. Responses were normalized to the unmodified GA9A aptamer and fold enhancements at indicated positions with either indole or phenol modifications are shown in the above bar graph. KDs were determined based on a 1:1 binding model. T4 indole modified aptamer is 1.8 pM, T12 indole modified aptamer is 1.2 pM and T12 phenol modified aptamer is 264 pM.
Raptamer Discovery Group are scientists and engineers with decades of experience working with nucleic acids and aptamers. The company not only provides unique products to customers but also is actively involved in research to improve aptamer performance. Our scientists have published in respected journals, such as Nature and Nucleic Acid Research, and we have worked with leading companies and research institutes around the world.
RDG is part of a much larger, private company with annual revenues over the past 5 years averaging more than $300 million. We are committed to quality and great customer service, and aspire to being the premier commercial aptamer discovery organization in the world. We continue to invest in innovation and improvement, and have worked with many leading institutions and companies around the world, including: